Takahashi Atsuhiko, Kushiro Toshio
Nihon University Health Planning Center, Nihon University School of Medicine.
Nihon Rinsho. 2008 Aug;66(8):1591-5.
Metabolic syndrome is considered as clustering of cardiovascular risk factors related to insulin resistance. Pioglitazone is one of thiazolidinediones that acts as insulin sensitizer. Since insulin resistance plays a role in pathogenesis of hypertension, pioglitazone may subserve antihypertensive effect in subjects with metabolic syndrome. We reviewed literatures about the effects of pioglitazone on blood pressure. Although blood pressure lowering effect of pioglitazone is small, several clinical trials and a meta-analysis indicated that it decreases both systolic and diastolic blood pressure. Pioglitazone has favorable effects on important components of metabolic syndrome including blood pressure.
代谢综合征被认为是与胰岛素抵抗相关的心血管危险因素的聚集。吡格列酮是噻唑烷二酮类药物之一,可作为胰岛素增敏剂。由于胰岛素抵抗在高血压发病机制中起作用,吡格列酮可能对代谢综合征患者具有降压作用。我们回顾了关于吡格列酮对血压影响的文献。尽管吡格列酮的降压作用较小,但多项临床试验和一项荟萃分析表明,它可降低收缩压和舒张压。吡格列酮对代谢综合征的重要组成部分(包括血压)具有有益作用。